Mus musculus
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA384994 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR5489140.fastq.gz | Fastqsanger.gz | |||
| SRR5489150.fastq.gz | Fastqsanger.gz | |||
| SRR5489160.fastq.gz | Fastqsanger.gz | |||
| SRR5489170.fastq.gz | Fastqsanger.gz | |||
| SRR5489180.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 58 |
Similar Datasets
Project description:MEF2C is a transcription factor with wide ranging roles and has specifically been implicated in restraining the microglial inflammatory response, participating in nervous system development, and contributing to aging and neurological disease. While MEF2C murine models have provided critical insights, the homeostatic and disease-associated functions of MEF2C in human microglia remain unclear. To examine this question, we profile microglia differentiated from isogenic, CRISPR-modified MEF2C haploinsufficient and knockout induced-pluripotent stem cell (iPSC) lines. A combination of transcriptomic, epigenetic and functional analyses revealed that loss of MEF2C leads to a hyperinflammatory microglial phenotype with broad impairment in phagocytosis, lipid accumulation, lysosomal dysfunction and elevated basal inflammatory cytokine and inflammasome activation. Transcriptomic and epigenetic approaches identified substantial overlap between reduced microglial MEF2C expression and primary brain idiopathic autism datasets, suggesting a broader role of microglial MEF2C dysregulation in idiopathic autism especially as relates to the transcription factors repressive functions. Reduced MEF2C expression has been associated with brain aging, and we find that reduction in MEF2C leads to a premature aging or senescence associated phenotype in microglia. These findings are extended to a murine xenotransplantation model wherein reductions in MEF2C expression in human microglia leads to an ameboid hyperinflammatory phenotype with lysosomal and lipid dysfunction. Taken together, these studies reveal novel aspects of microglial MEF2C function that contribute to homeostasis and development of neurological disease.
2025-10-01 | GSE306987 | GEO
Project description:MEF2C is a transcription factor with wide ranging roles and has specifically been implicated in restraining the microglial inflammatory response, participating in nervous system development, and contributing to aging and neurological disease. While MEF2C murine models have provided critical insights, the homeostatic and disease-associated functions of MEF2C in human microglia remain unclear. To examine this question, we profile microglia differentiated from isogenic, CRISPR-modified MEF2C haploinsufficient and knockout induced-pluripotent stem cell (iPSC) lines. A combination of transcriptomic, epigenetic and functional analyses revealed that loss of MEF2C leads to a hyperinflammatory microglial phenotype with broad impairment in phagocytosis, lipid accumulation, lysosomal dysfunction and elevated basal inflammatory cytokine and inflammasome activation. Transcriptomic and epigenetic approaches identified substantial overlap between reduced microglial MEF2C expression and primary brain idiopathic autism datasets, suggesting a broader role of microglial MEF2C dysregulation in idiopathic autism especially as relates to the transcription factors repressive functions. Reduced MEF2C expression has been associated with brain aging, and we find that reduction in MEF2C leads to a premature aging or senescence associated phenotype in microglia. These findings are extended to a murine xenotransplantation model wherein reductions in MEF2C expression in human microglia leads to an ameboid hyperinflammatory phenotype with lysosomal and lipid dysfunction. Taken together, these studies reveal novel aspects of microglial MEF2C function that contribute to homeostasis and development of neurological disease.
2025-10-01 | GSE306992 | GEO
Project description:MEF2C is a transcription factor with wide ranging roles and has specifically been implicated in restraining the microglial inflammatory response, participating in nervous system development, and contributing to aging and neurological disease. While MEF2C murine models have provided critical insights, the homeostatic and disease-associated functions of MEF2C in human microglia remain unclear. To examine this question, we profile microglia differentiated from isogenic, CRISPR-modified MEF2C haploinsufficient and knockout induced-pluripotent stem cell (iPSC) lines. A combination of transcriptomic, epigenetic and functional analyses revealed that loss of MEF2C leads to a hyperinflammatory microglial phenotype with broad impairment in phagocytosis, lipid accumulation, lysosomal dysfunction and elevated basal inflammatory cytokine and inflammasome activation. Transcriptomic and epigenetic approaches identified substantial overlap between reduced microglial MEF2C expression and primary brain idiopathic autism datasets, suggesting a broader role of microglial MEF2C dysregulation in idiopathic autism especially as relates to the transcription factors repressive functions. Reduced MEF2C expression has been associated with brain aging, and we find that reduction in MEF2C leads to a premature aging or senescence associated phenotype in microglia. These findings are extended to a murine xenotransplantation model wherein reductions in MEF2C expression in human microglia leads to an ameboid hyperinflammatory phenotype with lysosomal and lipid dysfunction. Taken together, these studies reveal novel aspects of microglial MEF2C function that contribute to homeostasis and development of neurological disease.
2025-10-01 | GSE306989 | GEO
Project description:Here we report that activation of cyclic GMP-AMP synthase (cGAS) diminishes cognitive resilience by decreasing the neuronal transcriptional network of myocyte enhancer factor 2c (MEF2C) through type I interferon (IFN-I) signaling. Pathogenic tau activates cGAS and IFN-I responses in microglia, in part mediated by cytosolic leakage of mitochondrial DNA. Genetic ablation of cGAS in tauopathy mice diminished microglial IFN-I response, preserved synapse integrity and plasticity, and protected against cognitive impairment without affecting the pathogenic tau load. cGAS ablation enhanced, while activation of IFN-I downregulated, neuronal MEF2C expression network linked with cognitive resilience in AD.
2023-04-26 | GSE226381 | GEO
Project description:MEF2C encodes a transcription factor that is critical in nervous system development. To examine disease-associated functions of MEF2C in human microglia, we profiled microglia differentiated from isogenic MEF2C-haploinsufficient and -knockout induced pluripotent stem cell lines. Complementary transcriptomic and functional analyses revealed that loss of MEF2C lead to a hyperinflammatory phenotype with broad phagocytic impairment, lipid accumulation, lysosomal dysfunction, and elevated basal inflammatory cytokine secretion. Genome-wide profiling of MEF2C-bound sites coupled with the active regulatory landscape enabled inference of its transcriptional functions and potential mechanisms for MEF2C-associated cellular functions. Transcriptomic and epigenetic approaches identified substantial overlap with idiopathic autism datasets, suggesting a broader role of human microglial MEF2C dysregulation in idiopathic autism. In a murine xenotransplantation model, loss of MEF2C led to morphological, lysosomal and lipid abnormalities in human microglia in vivo. Altogether, these studies reveal mechanisms by which reduced microglial MEF2C could contribute to the development of neurological diseases.
2025-10-01 | GSE270436 | GEO
Project description:Type I conventional dendritic cells (cDC1s) are an essential antigen-presenting population, required for generating adaptive immunity against intracellular pathogens and tumors. While the transcriptional control of cDC1 development is well understood, the mechanisms by which extracellular stimuli affect cDC1 function remain unclear. Recently, we demonstrated that the cytokine IL-10 inhibits cDC1 maturation induced upon polyinosinic-polycytidylic acid (poly I:C) exposure via a STAT3-dependent mechanism. Furthermore, utilizing a tumor vaccine strategy, we found STAT3 restrains cDC1-mediated anti-tumor immunity. To understand the pathways by which IL-10 and STAT3 regulate cDC1s, we evaluated transcriptional responses by RNA-sequencing. Bioinformatic analyses indicated that many inflammatory pathways were enriched in cDC1s following poly I:C treatment, while interferon (IFN) signaling was uniquely inhibited by STAT3 upon concomitant exposure to IL-10. We found that poly I:C stimulated production of IFN-b and IFN-g from cDC1s. Concurrent exposure to IL-10 suppressed IFN-b and IFN-g secretion as well as accrual of phosphorylated STAT1 and expression of the IFN-response gene Cxcl10 in cDC1s. By contrast, Stat3-deficient cDC1s were refractory to IL-10, indicating STAT3 controls poly I:C-mediated IFN production and IFN transcriptional responses in cDC1s. Moreover, we found that maturation of cDC1s in response to poly I:C is dependent on the type I IFN receptor. Taken together, our data indicate STAT3 is essential for restraining autocrine type I IFN signaling in cDC1s elicited by poly I:C stimulation.
2022-07-26 | GSE188995 | GEO
Project description:Neuroinflammation driven by microglial overactivation is a significant contributor across a diverse range of neurological disorders. While MEF2C mutations have been associated with a syndromic form of autism spectrum disorder (ASD) and various other neurological disorders in humans, the role of MEF2C as a key immune checkpoint to restrain microglial overactivation remains elusive. In this study, we established MEF2C-knockout (KO) induced microglia-like cells (iMGLs) via differentiation of corresponding human pluripotent stem cells, and subsequently treated with LPS, as a disease model of overactivated microglia. Through high-throughput screening, we identified BMS265246, a CDK2 inhibitor, which effectively normalized overactivated phenotypes in LPS-stimulated MEF2C-KO iMGLs, nearing levels seen in WT counterparts. Mechanistically, absence of MEF2C instigated a sequential cascade encompassing p21 downregulation, CDK2 activation, RB phosphorylation and degradation, and NF-κB p65 subunit nuclear translocation, thereby intensifying inflammatory responses. Remarkably, BMS265246 treatment significantly rectified microglial overactivation and ASD behavioral defects in both global and microglia-specific Mef2C heterozygous mice. Overall, our findings elucidate a novel protective mechanism governed by MEF2C, and unveil CDK2 as a promising therapeutic target for treating various diseases influenced by overactivated microglia with aberrant MEF2C expression and/or CDK2 activation.
2023-10-24 | GSE245677 | GEO
Project description:Intrinsic immune checkpoints in microglia are vital for maintaining homeostatic immune response and preventing overactivation. Neuroinflammation, frequently driven by microglial overactivation, significantly influences a wide range of neurological disorders. While MEF2C has been associated with a syndromic form of autism spectrum disorder (ASD) and various other neurological disorders in humans, its specific role as an immune checkpoint remains poorly defined. By harnessing MEF2C-knockout (KO) induced microglia-like cells (iMGLs) through differentiation from human pluripotent stem cells (hPSCs), here we observed that these cells, following LPS stimulation, exhibited overactivation similar to patterns seen in various neurological disorders. High-throughput screening identified BMS265246, a CDK2 inhibitor, as effective in specifically suppressing the overactivated phenotypes of MEF2C-KO iMGLs, and in restoring inflammatory response closer to normal levels. Mechanistically, we uncovered that MEF2C regulates p21 transcription, a critical step in preventing CDK2 activation in microglia. Loss of MEF2C results in CDK2-induced RB phosphorylation and degradation, leading to enhanced NF-κB p65 subunit nuclear translocation and exacerbated inflammatory responses. Remarkably, BMS265246 treatment rectified microglial overactivation and ASD-like behaviors in both global and microglia-specific Mef2C heterozygous knockout mice. Overall, our findings elucidated a previously unknown immune checkpoint mechanism governed by MEF2C, and highlighted CDK2 as a potential key factor driving neuroinflammation through microglial overactivation. These insights positions CDK2 as a promising therapeutic target for treating various neurological diseases influenced by overactivated microglia.
2025-05-09 | GSE277121 | GEO
Project description:Neuropsychiatric complications including depression and cognitive decline develop in the years after traumatic brain injury (TBI), negatively affecting quality of life. Microglial and type 1 interferon (IFN-I) responses are associated with the transition from acute to chronic neuroinflammation after diffuse TBI in mice. Thus, the purpose of this study was to determine if impaired neuronal homeostasis and increased IFN-I responses intersected after TBI to cause cognitive impairment. Here, the RNA profile of neurons and microglia after TBI (single nucleus RNA-sequencing) with or without microglia depletion (CSF1R antagonist) was assessed 7 dpi. There was a TBI-dependent suppression of cortical neuronal homeostasis with reductions in CREB signaling, synaptogenesis, and synaptic migration and increases in RhoGDI and PTEN signaling (Ingenuity Pathway Analysis). Microglial depletion reversed 50% of TBI-induced gene changes in cortical neurons depending on subtype. Moreover, the microglial RNA signature 7 dpi was associated with increased stimulator of interferon genes (STING) activation and IFN-I responses. Therefore, we sought to reduce IFN-I signaling after TBI using STING knockout mice and a STING antagonist, chloroquine (CQ). TBI-associated cognitive deficits in novel object location and recognition (NOL/NOR) tasks at 7 and 30 dpi were STING dependent. In addition, TBI-induced STING expression, microglial morphological restructuring, inflammatory (Tnf, Cd68, Ccl2) and IFN-related (Irf3, Irf7, Ifi27) gene expression in the cortex were attenuated in STINGKO mice. CQ also reversed TBI-induced cognitive deficits and reduced TBI-induced inflammatory (Tnf, Cd68, Ccl2) and IFN (Irf7, Sting) cortical gene expression. Collectively, reducing IFN-I signaling after TBI with STING-dependent interventions attenuated the prolonged microglial activation and cognitive impairment.
2025-06-05 | GSE299005 | GEO
Project description:Prenatal infections and activation of the maternal immune system have been proposed to contribute to causing neurodevelopmental disorders (NDDs), chronic conditions often linked to brain abnormalities. Microglia are the resident immune cells of the brain and play a key role in neurodevelopment. Disruption of microglial functions can lead to brain abnormalities and increase the risk of developing NDDs. How the maternal as well as the fetal immune system affect human neurodevelopment and contribute to NDDs remains unclear. An important reason for this knowledge gap is the fact that the impact of exposure to prenatal risk factors has been challenging to study in the human context. Here, we characterized a model of cerebral organoids (CO) with integrated microglia (COiMg). These organoids express typical microglial markers and respond to inflammatory stimuli. The presence of microglia influences cerebral organoid development, including cell density and neural differentiation, and regulates the expression of several ciliated and mesenchymal cell markers. Moreover, COiMg and organoids without microglia show similar but also distinct responses to inflammatory stimuli. Additionally, IFN-γ induced significant transcriptional and structural changes in the cerebral organoids, that appear to be regulated by the presence of microglia. Specifically, interferon-gamma (IFN-γ) was found to alter the expression of genes linked to autism. This model provides a valuable tool to study how inflammatory perturbations and microglial presence affect neurodevelopmental processes.
2025-01-29 | GSE281451 | GEO